• Discover Astex
    • Our Mission & Values
    • Our Leadership Team
    • Our History
    • Corporate Social Responsibility
  • R&D
    • Clinical Pipeline
      • Partnered Products and Programs
        • Kisqali® (ribociclib) CDK4/6 inhibitor (Oncology)
        • Balversa® (erdafitinib) FGFr inhibitor (Oncology)
        • Truqap® PKB/Akt Inhibitor (Oncology)
        • KRAS Oncogene (Oncology)
        • Beroterkib (ASTX029) Extracellular Signal-Related Protein Kinases (ERK 1/2) Inhibitor (Solid Tumors)
        • ASTX295 Oral Murine Double Minute 2 (MDM2) antagonist (Solid Tumors)
        • SHP2 (Oncology)
        • P53 tumour suppressor protein (Oncology)
      • Proprietary Products and Programs
        • Tolinapant (ASTX660) Dual IAP Antagonist (T-cell Lymphomas)
    • Pyramid™ Discovery Platform
    • Oncology and CNS Discovery
    • Sustaining Innovation Postdocs
  • Partnering
  • Our People & Culture
    • Career Opportunities
  • Media
    • Press Releases
    • Conferences & Meetings
    • Presentations & Publications
    • Interactive Scientific Resources
      • Interactive Software
    • Astex in the News
  • Contact
  • Click to open the search input field Click to open the search input field Search
  • Menu Menu
You are here: Home1 / 20092 / Astex Announces a CRADA with the National Cancer Institute for its HSP90...

Astex Announces a CRADA with the National Cancer Institute for its HSP90 inhibitor AT13387

3 November 2009/in 2009, News

Astex Announces a CRADA with the National Cancer Institute for its HSP90 inhibitor AT13387

https://astx.com/wp-content/uploads/2023/12/New_Home_Logo_RGB.svg 0 0 webadmin https://astx.com/wp-content/uploads/2023/12/New_Home_Logo_RGB.svg webadmin2009-11-03 12:35:172016-11-28 12:35:51Astex Announces a CRADA with the National Cancer Institute for its HSP90 inhibitor AT13387

© Astex Pharmaceuticals
All rights reserved

astex

Useful links

  • Home
  • Sitemap
  • Privacy Policy
  • Terms of Use
  • Legal
  • LinkedIn

Member of the Otsuka Group

A selection of photos on this website
is courtesy of Valerio Berdini

Link to: SuperGen Reports 2009 Third Quarter Financial Results Link to: SuperGen Reports 2009 Third Quarter Financial Results SuperGen Reports 2009 Third Quarter Financial Results Link to: Astex to disclose the structure of its HSP90 inhibitor, AT13387, at the AACR-NCI-EORTC Annual Meeting 2009 Link to: Astex to disclose the structure of its HSP90 inhibitor, AT13387, at the AACR-NCI-EORTC Annual Meeting 2009 Astex to disclose the structure of its HSP90 inhibitor, AT13387, at the AACR-NCI-EORTC...
Scroll to top Scroll to top Scroll to top
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.Ok